RU2004135541A - Иммуногенные композиции - Google Patents
Иммуногенные композиции Download PDFInfo
- Publication number
- RU2004135541A RU2004135541A RU2004135541/13A RU2004135541A RU2004135541A RU 2004135541 A RU2004135541 A RU 2004135541A RU 2004135541/13 A RU2004135541/13 A RU 2004135541/13A RU 2004135541 A RU2004135541 A RU 2004135541A RU 2004135541 A RU2004135541 A RU 2004135541A
- Authority
- RU
- Russia
- Prior art keywords
- protein
- spp
- virus
- cancer
- fusion
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 10
- 230000002163 immunogen Effects 0.000 title claims 8
- 102000004169 proteins and genes Human genes 0.000 claims 21
- 108090000623 proteins and genes Proteins 0.000 claims 21
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 10
- 108020001507 fusion proteins Proteins 0.000 claims 9
- 102000037865 fusion proteins Human genes 0.000 claims 9
- 239000002671 adjuvant Substances 0.000 claims 6
- 230000004927 fusion Effects 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims 3
- 229960001231 choline Drugs 0.000 claims 3
- 230000001939 inductive effect Effects 0.000 claims 3
- 238000012737 microarray-based gene expression Methods 0.000 claims 3
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims 3
- 150000007523 nucleic acids Chemical group 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 201000010893 malignant breast melanoma Diseases 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 102100022144 Achaete-scute homolog 2 Human genes 0.000 claims 1
- 102100024003 Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 1 Human genes 0.000 claims 1
- 102100035526 B melanoma antigen 1 Human genes 0.000 claims 1
- 241000588807 Bordetella Species 0.000 claims 1
- 241000589968 Borrelia Species 0.000 claims 1
- -1 CASB616 Proteins 0.000 claims 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 claims 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims 1
- 201000006082 Chickenpox Diseases 0.000 claims 1
- 241000606161 Chlamydia Species 0.000 claims 1
- 241001647372 Chlamydia pneumoniae Species 0.000 claims 1
- 241000606153 Chlamydia trachomatis Species 0.000 claims 1
- 241000701022 Cytomegalovirus Species 0.000 claims 1
- 241000588722 Escherichia Species 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 241000710831 Flavivirus Species 0.000 claims 1
- 241000589989 Helicobacter Species 0.000 claims 1
- 241000711549 Hepacivirus C Species 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 claims 1
- 241000724675 Hepatitis E virus Species 0.000 claims 1
- 206010019799 Hepatitis viral Diseases 0.000 claims 1
- 241000709721 Hepatovirus A Species 0.000 claims 1
- 101000901109 Homo sapiens Achaete-scute homolog 2 Proteins 0.000 claims 1
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 claims 1
- 101000628547 Homo sapiens Metalloreductase STEAP1 Proteins 0.000 claims 1
- 101000874141 Homo sapiens Probable ATP-dependent RNA helicase DDX43 Proteins 0.000 claims 1
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 1
- 241000701806 Human papillomavirus Species 0.000 claims 1
- 102100034872 Kallikrein-4 Human genes 0.000 claims 1
- 241000186781 Listeria Species 0.000 claims 1
- 208000016604 Lyme disease Diseases 0.000 claims 1
- 241000712079 Measles morbillivirus Species 0.000 claims 1
- 102100026712 Metalloreductase STEAP1 Human genes 0.000 claims 1
- 241000588621 Moraxella Species 0.000 claims 1
- 102100034256 Mucin-1 Human genes 0.000 claims 1
- 108010008707 Mucin-1 Proteins 0.000 claims 1
- 241000711386 Mumps virus Species 0.000 claims 1
- 101100369076 Mus musculus Tdgf1 gene Proteins 0.000 claims 1
- 241000186359 Mycobacterium Species 0.000 claims 1
- 241000588653 Neisseria Species 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 102000036673 PRAME Human genes 0.000 claims 1
- 108060006580 PRAME Proteins 0.000 claims 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims 1
- 102100021768 Phosphoserine aminotransferase Human genes 0.000 claims 1
- 241000224016 Plasmodium Species 0.000 claims 1
- 241000223960 Plasmodium falciparum Species 0.000 claims 1
- 102100035724 Probable ATP-dependent RNA helicase DDX43 Human genes 0.000 claims 1
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 241000725643 Respiratory syncytial virus Species 0.000 claims 1
- 241000702670 Rotavirus Species 0.000 claims 1
- 241000607142 Salmonella Species 0.000 claims 1
- 241000700584 Simplexvirus Species 0.000 claims 1
- 241000191940 Staphylococcus Species 0.000 claims 1
- 241000191963 Staphylococcus epidermidis Species 0.000 claims 1
- 102000000763 Survivin Human genes 0.000 claims 1
- 108010002687 Survivin Proteins 0.000 claims 1
- 108010017842 Telomerase Proteins 0.000 claims 1
- 241000223996 Toxoplasma Species 0.000 claims 1
- 102000003425 Tyrosinase Human genes 0.000 claims 1
- 108060008724 Tyrosinase Proteins 0.000 claims 1
- 206010046980 Varicella Diseases 0.000 claims 1
- 150000001413 amino acids Chemical group 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 231100000249 enterotoxic Toxicity 0.000 claims 1
- 230000002242 enterotoxic effect Effects 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 1
- 230000001024 immunotherapeutic effect Effects 0.000 claims 1
- 108010024383 kallikrein 4 Proteins 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 108040000983 polyphosphate:AMP phosphotransferase activity proteins Proteins 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 235000002020 sage Nutrition 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 241000712461 unidentified influenza virus Species 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
- A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001189—PRAME
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001194—Prostate specific antigen [PSA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
- C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Transplantation (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0213365.0 | 2002-06-11 | ||
| GBGB0213365.0A GB0213365D0 (en) | 2002-06-11 | 2002-06-11 | Novel compounds |
| GB0300914A GB0300914D0 (en) | 2003-01-15 | 2003-01-15 | Vaccines |
| GB0300914.9 | 2003-01-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2004135541A true RU2004135541A (ru) | 2005-10-10 |
Family
ID=29738082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2004135541/13A RU2004135541A (ru) | 2002-06-11 | 2003-06-06 | Иммуногенные композиции |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20060147477A1 (https=) |
| EP (1) | EP1511768B1 (https=) |
| JP (1) | JP2006512047A (https=) |
| KR (1) | KR20050010040A (https=) |
| CN (1) | CN100360558C (https=) |
| AR (1) | AR040178A1 (https=) |
| AT (1) | ATE359295T1 (https=) |
| AU (1) | AU2003246411A1 (https=) |
| BR (1) | BR0311732A (https=) |
| CA (1) | CA2487831A1 (https=) |
| CO (1) | CO5631450A2 (https=) |
| DE (1) | DE60313163T2 (https=) |
| DK (1) | DK1511768T3 (https=) |
| ES (1) | ES2285174T3 (https=) |
| IL (1) | IL165372A0 (https=) |
| IS (1) | IS7547A (https=) |
| MX (1) | MXPA04012443A (https=) |
| MY (1) | MY139557A (https=) |
| NO (1) | NO20045148L (https=) |
| NZ (1) | NZ537125A (https=) |
| PE (1) | PE20040554A1 (https=) |
| PL (1) | PL374534A1 (https=) |
| PT (1) | PT1511768E (https=) |
| RU (1) | RU2004135541A (https=) |
| TW (1) | TW200400970A (https=) |
| UY (1) | UY27840A1 (https=) |
| WO (1) | WO2003104272A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2598265C2 (ru) * | 2013-07-26 | 2016-09-20 | Амир Закиевич Максютов | Полиэпитопные иммуногенные полипептиды и способы их применения |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10144906B4 (de) | 2001-09-12 | 2013-11-28 | Novartis Vaccines And Diagnostics Gmbh | Verfahren zur großtechnischen Herstellung von Impfstoffen |
| GB0321615D0 (en) | 2003-09-15 | 2003-10-15 | Glaxo Group Ltd | Improvements in vaccination |
| EP2269638A3 (en) * | 2004-05-28 | 2012-06-13 | GlaxoSmithKline Biologicals S.A. | Vaccine compositions comprising virosomes and a saponin adjuvant |
| US8501198B2 (en) | 2004-06-07 | 2013-08-06 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to treat cancers |
| US9107864B2 (en) | 2004-06-07 | 2015-08-18 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to treat cancers |
| GB0417494D0 (en) * | 2004-08-05 | 2004-09-08 | Glaxosmithkline Biolog Sa | Vaccine |
| CA2595778A1 (en) * | 2005-01-28 | 2006-08-03 | Ramot At Tel Aviv University, Ltd. | Anti-muc1 .alpha..beta. antibodies |
| US8252740B2 (en) * | 2006-01-27 | 2012-08-28 | The University Of Mississippi Medical Center | Thermally-targeted delivery of medicaments including doxorubicin |
| EP2032719A2 (en) | 2006-06-02 | 2009-03-11 | GlaxoSmithKline Biologicals S.A. | Method for identifying whether a patient will be responder or not to immunotherapy |
| SG177141A1 (en) * | 2006-12-06 | 2012-01-30 | Novartis Ag | Vaccines including antigen from four strains of influenza virus |
| ES2321788B1 (es) * | 2007-01-29 | 2010-03-11 | Universidad Miguel Hernandez | Dominios proteicos de afinidad a colina para mejorar la expresion, inmovilizacion y purificacion de polipetidos. |
| GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
| WO2009046739A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating prostate cancer (pca) |
| PT2268618E (pt) | 2008-03-03 | 2015-10-12 | Novartis Ag | Compostos e composições moduladores da actividade tlr |
| WO2009114202A2 (en) * | 2008-03-14 | 2009-09-17 | The United States Of America As Represented By The Secretary Of The Navy | Vaccine and immunization method using plasmodium antigen 2 |
| US8501926B2 (en) * | 2008-09-24 | 2013-08-06 | The Johns Hopkins University | Malaria vaccine |
| WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| WO2010092479A2 (en) | 2009-02-10 | 2010-08-19 | Novartis Ag | Influenza vaccines with reduced amounts of squalene |
| US20110229514A1 (en) * | 2009-03-16 | 2011-09-22 | Denise Doolan | Vaccine and immunization method using plasmodium antigen 2 |
| EP3017826A1 (en) | 2009-03-24 | 2016-05-11 | Novartis AG | Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates |
| CA2765112A1 (en) | 2009-06-10 | 2010-12-16 | Novartis Ag | Benzonaphthyridine-containing vaccines |
| JO3257B1 (ar) | 2009-09-02 | 2018-09-16 | Novartis Ag | مركبات وتركيبات كمعدلات لفاعلية tlr |
| ES2443952T3 (es) | 2009-09-02 | 2014-02-21 | Novartis Ag | Composiciones inmunógenas que incluyen moduladores de la actividad de TLR |
| CN102695523A (zh) | 2009-09-10 | 2012-09-26 | 诺华有限公司 | 针对呼吸道疾病的组合疫苗 |
| GB0917457D0 (en) | 2009-10-06 | 2009-11-18 | Glaxosmithkline Biolog Sa | Method |
| WO2011057148A1 (en) | 2009-11-05 | 2011-05-12 | Irm Llc | Compounds and compositions as tlr-7 activity modulators |
| SG10201501980SA (en) | 2009-12-15 | 2015-05-28 | Novartis Ag | Homogeneous suspension of immunopotentiating compounds and uses thereof |
| SI2528621T1 (sl) * | 2010-01-27 | 2017-01-31 | Glaxosmithkline Biologicals S.A., | Modificirani tuberkolozni antigeni |
| AU2011232421B2 (en) | 2010-03-23 | 2015-08-13 | Novartis Ag | Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc. |
| NZ702796A (en) | 2010-07-26 | 2017-03-31 | Qu Biologics Inc | Immunogenic anti-inflammatory compositions |
| WO2012072769A1 (en) | 2010-12-01 | 2012-06-07 | Novartis Ag | Pneumococcal rrgb epitopes and clade combinations |
| KR102049928B1 (ko) | 2011-08-17 | 2019-11-28 | 글로브이뮨 | 효모-muc1 면역요법 조성물 및 그 용도 |
| JP2015510872A (ja) | 2012-03-07 | 2015-04-13 | ノバルティス アーゲー | Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ抗原の増強された製剤 |
| JP6411378B2 (ja) | 2013-02-01 | 2018-10-24 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Ｔｏｌｌ様受容体アゴニストを含む免疫学的組成物の皮内送達 |
| JP6632607B2 (ja) | 2014-05-02 | 2020-01-22 | クー バイオロジックス インク．Ｑｕ Ｂｉｏｌｏｇｉｃｓ Ｉｎｃ． | 抗微生物免疫修飾 |
| CN108164586B (zh) * | 2018-01-22 | 2021-03-26 | 西南医科大学 | 合成多肽及其应用 |
| ES2985591T3 (es) | 2018-02-12 | 2024-11-06 | Inimmune Corp | Ligandos de receptores tipo Toll |
| FR3100819B1 (fr) * | 2019-09-18 | 2024-04-19 | Centre Nat Rech Scient | Production et fonctionnalisation de nanoparticules dérivées du phage T5 et utilisations thérapeutiques |
| CN110922455B (zh) * | 2019-12-28 | 2023-01-13 | 重庆艾力彼生物科技有限公司 | 铜绿假单胞菌疫苗重组蛋白rePilA-FliC及制备方法和应用 |
| KR20230098825A (ko) | 2020-11-04 | 2023-07-04 | 엘리고 바이오사이언스 | 씨. 아크네스 개체군에게 dna 페이로드의 원위치 전달을 위한 파지-유래 입자 |
| CN113278078B (zh) * | 2021-05-25 | 2023-03-21 | 西南医科大学 | 多肽序列及其应用 |
| CN116875520B (zh) * | 2023-07-12 | 2024-06-14 | 吉林农业大学 | 表达核糖体失活蛋白的乳酸菌及其在抗轮状病毒中的应用 |
| CN117003890B (zh) * | 2023-08-09 | 2024-06-04 | 成都新诺明生物科技有限公司 | 一种含有P2和两个Fc的gE融合蛋白及其制备方法和应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6395278B1 (en) * | 1997-02-25 | 2002-05-28 | Corixa Corporation | Prostate specific fusion protein compositions |
| US6090388A (en) * | 1998-06-20 | 2000-07-18 | United Biomedical Inc. | Peptide composition for prevention and treatment of HIV infection and immune disorders |
| TWI227241B (en) * | 1998-06-20 | 2005-02-01 | United Biomedical Inc | IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate |
| CN100419079C (zh) * | 1998-07-14 | 2008-09-17 | 科里克萨有限公司 | 用于治疗和诊断前列腺癌的组合物和方法 |
| WO2000029434A2 (en) * | 1998-11-19 | 2000-05-25 | St. Jude Children's Research Hospital | PNEUMOCOCCAL CHOLINE BINDING PROTEINS, CbpG AND CbpD, DIAGNOSTIC AND THERAPEUTIC USES THEREOF |
| EP1230364A2 (en) * | 1999-11-12 | 2002-08-14 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| IL150732A0 (en) * | 2000-01-14 | 2003-02-12 | Corixa Corp | Prostate specific polypeptides, polynucleotides that encode said polypeptides and pharmaceutical compositions containing the same |
| CA2403909A1 (en) * | 2000-03-27 | 2001-10-04 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
-
2003
- 2003-06-06 IL IL16537203A patent/IL165372A0/xx unknown
- 2003-06-06 MX MXPA04012443A patent/MXPA04012443A/es not_active Application Discontinuation
- 2003-06-06 WO PCT/EP2003/006096 patent/WO2003104272A1/en not_active Ceased
- 2003-06-06 CN CNB038194872A patent/CN100360558C/zh not_active Expired - Fee Related
- 2003-06-06 JP JP2004511340A patent/JP2006512047A/ja active Pending
- 2003-06-06 EP EP03757056A patent/EP1511768B1/en not_active Expired - Lifetime
- 2003-06-06 RU RU2004135541/13A patent/RU2004135541A/ru not_active Application Discontinuation
- 2003-06-06 CA CA002487831A patent/CA2487831A1/en not_active Abandoned
- 2003-06-06 PL PL03374534A patent/PL374534A1/xx not_active Application Discontinuation
- 2003-06-06 US US10/517,420 patent/US20060147477A1/en not_active Abandoned
- 2003-06-06 AU AU2003246411A patent/AU2003246411A1/en not_active Abandoned
- 2003-06-06 DK DK03757056T patent/DK1511768T3/da active
- 2003-06-06 KR KR10-2004-7020138A patent/KR20050010040A/ko not_active Withdrawn
- 2003-06-06 DE DE60313163T patent/DE60313163T2/de not_active Expired - Fee Related
- 2003-06-06 PT PT03757056T patent/PT1511768E/pt unknown
- 2003-06-06 NZ NZ537125A patent/NZ537125A/en unknown
- 2003-06-06 BR BR0311732-4A patent/BR0311732A/pt not_active IP Right Cessation
- 2003-06-06 ES ES03757056T patent/ES2285174T3/es not_active Expired - Lifetime
- 2003-06-06 AT AT03757056T patent/ATE359295T1/de not_active IP Right Cessation
- 2003-06-09 MY MYPI20032146A patent/MY139557A/en unknown
- 2003-06-09 PE PE2003000573A patent/PE20040554A1/es not_active Application Discontinuation
- 2003-06-09 UY UY27840A patent/UY27840A1/es unknown
- 2003-06-09 AR ARP030102046A patent/AR040178A1/es not_active Application Discontinuation
- 2003-06-09 TW TW092115540A patent/TW200400970A/zh unknown
-
2004
- 2004-11-23 IS IS7547A patent/IS7547A/is unknown
- 2004-11-25 NO NO20045148A patent/NO20045148L/no not_active Application Discontinuation
- 2004-12-06 CO CO04122511A patent/CO5631450A2/es not_active Application Discontinuation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2598265C2 (ru) * | 2013-07-26 | 2016-09-20 | Амир Закиевич Максютов | Полиэпитопные иммуногенные полипептиды и способы их применения |
Also Published As
| Publication number | Publication date |
|---|---|
| DK1511768T3 (da) | 2007-08-20 |
| ATE359295T1 (de) | 2007-05-15 |
| MXPA04012443A (es) | 2005-04-19 |
| CN1675237A (zh) | 2005-09-28 |
| JP2006512047A (ja) | 2006-04-13 |
| AU2003246411A1 (en) | 2003-12-22 |
| PE20040554A1 (es) | 2004-09-30 |
| DE60313163D1 (de) | 2007-05-24 |
| HK1074846A1 (en) | 2005-11-25 |
| KR20050010040A (ko) | 2005-01-26 |
| NZ537125A (en) | 2006-08-31 |
| MY139557A (en) | 2009-10-30 |
| DE60313163T2 (de) | 2008-01-03 |
| CN100360558C (zh) | 2008-01-09 |
| EP1511768B1 (en) | 2007-04-11 |
| AR040178A1 (es) | 2005-03-16 |
| PT1511768E (pt) | 2007-07-16 |
| US20060147477A1 (en) | 2006-07-06 |
| TW200400970A (en) | 2004-01-16 |
| ES2285174T3 (es) | 2007-11-16 |
| EP1511768A1 (en) | 2005-03-09 |
| WO2003104272A1 (en) | 2003-12-18 |
| NO20045148L (no) | 2005-03-01 |
| BR0311732A (pt) | 2005-03-01 |
| IS7547A (is) | 2004-11-23 |
| CO5631450A2 (es) | 2006-04-28 |
| IL165372A0 (en) | 2006-01-15 |
| CA2487831A1 (en) | 2003-12-18 |
| PL374534A1 (en) | 2005-10-31 |
| UY27840A1 (es) | 2003-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2004135541A (ru) | Иммуногенные композиции | |
| JP2006512047A5 (https=) | ||
| Shedlock et al. | DNA vaccination: antigen presentation and the induction of immunity | |
| CA2301920C (en) | Vaccine | |
| EP2130921B1 (en) | Vaccine for prevention and treatment of HIV-infection | |
| RU2006111849A (ru) | Иммуногенные композиции | |
| US20070212329A1 (en) | Vaccine Compositions Comprising An Interleukin 18 And Saponin Adjuvant System | |
| RU2011105448A (ru) | Применение ингибирующих tgf-бета1 пептидов для приготовления модулирующего иммунный ответ агента | |
| TW200902048A (en) | Vaccine | |
| JP2007508273A5 (https=) | ||
| CA2342289A1 (en) | Treatment of cervical cancer | |
| EP1545625A2 (en) | Flexible vaccine assembly and vaccine delivery platform | |
| AU2005232396B2 (en) | Vaccination against malignant melanoma using BCG and/or vaccinia | |
| EP2931896A1 (en) | Modified coiled coil type proteins having improved properties | |
| JP5717338B2 (ja) | 免疫療法のための潜在性ｈｌａ−ｂ７エピトープの同定、最適化及び使用 | |
| JP7777890B2 (ja) | Ｃｃｌ１１の用途 | |
| Vangasseri et al. | Lipid-protamine-DNA-mediated antigen delivery | |
| Montgomery et al. | Protein expression in vivo by injection of polynucleotides | |
| EP1165773A1 (en) | Advanced antigen presentation platform | |
| JP2021512966A5 (https=) | ||
| Webster | Potential advantages of DNA immunization for influenza epidemic and pandemic planning | |
| EP1748792B1 (en) | Compositions comprising demethylating agents as enhancers of immunotherapy for the treatment of chronic infections and neoplastic diseases and methods for treating the same | |
| WO2005091753A2 (en) | Flexible vaccine assembly and vaccine delivery platform | |
| EP3562504B1 (en) | Dna vaccine comprising a polynucleotide sequence encoding a fusion protein encompassing a plant protein signal sequence | |
| JP6975716B2 (ja) | 樹状細胞標的化ペプチド、当該ペプチドを利用したペプチド融合体、及び当該ペプチド融合体を利用したワクチン |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20081229 |
|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20081229 |